Latest News

The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.
Trastuzumab Deruxtecan Improves Survival in HER2+ Metastatic Gastric Cancer

March 5th 2025

The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.

Data from the RATIONALE-306 trial support the approval of tislelizumab plus chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma.
FDA Approves Frontline Tislelizumab/Chemo in Advanced PD-L1+ ESCC

March 4th 2025

Antitumor efficacy end points favored placebo over trilaciclib prior to FOLFOXIRI/bevacizumab in patients with untreated metastatic colorectal cancer.
Trilaciclib plus FOLFOXIRI/Bevacizumab Inhibits Myelosuppression in CRC

March 3rd 2025

In a small cohort of patients with MMS/pMMR CRC, the suvemcitug and envafolimab pharmacokinetic profiles were comparable with prior monotherapy studies.
Suvemcitug Combination Therapy Exhibits Safety, Activity in MSS/pMMR CRC

March 2nd 2025

CAN-2409/Valacyclovir Plus SOC Demonstrates Positive Survival in PDAC
CAN-2409/Valacyclovir Plus SOC Demonstrates Positive Survival in PDAC

February 27th 2025